
After Keytruda combo win, Gilead's Trodelvy meets the mark in solo breast cancer trial
After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug conjugate Trodelvy has impressed in a solo showing in a similar indication. In the late-stage Ascent-03 trial, Trodelvy bested …